NURS 6521 Midterm Exam (4 Versions, 400 Q and A, Year-2021) /
NURS 6521N Midterm Exam / NURS6521 Midterm Exam / NURS-
6521N Midterm Exam: Walden University | Correct Q and A
SECTION I: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–25)
1. A patient is prescribed a medication that undergoes extensive first-pass metabolism. The
nurse practitioner understands that this drug:
A. Will have increased bioavailability when administered orally
B. Will be metabolized in the liver before reaching systemic circulation
C. Must be administered intravenously to achieve any therapeutic effect
D. Will be excreted unchanged by the kidneys
Correct Answer: B
B. Will be metabolized in the liver before reaching systemic circulation
Rationale: First-pass metabolism occurs when an orally administered drug is absorbed from
the gastrointestinal tract and transported via the portal vein to the liver, where it undergoes
biotransformation before entering systemic circulation. This reduces the drug's oral
bioavailability. Drugs with extensive first-pass metabolism (e.g., nitroglycerin, morphine,
propranolol) often require higher oral doses or alternative routes of administration to achieve
therapeutic effects. Option A is incorrect because first-pass metabolism decreases, not
increases, oral bioavailability. Option C is incorrect because many drugs with first-pass
metabolism can still be given orally with appropriate dose adjustments. Option D is incorrect
because drugs undergoing first-pass metabolism are metabolized, not excreted unchanged .
2. A drug is 96% protein-bound. Which statement best describes the clinical implication of this
property?
A. The drug will have a rapid onset of action
B. A small change in protein binding can significantly increase free drug levels
C. The drug will be excreted more rapidly by the kidneys
D. The drug requires no dose adjustment in renal impairment
Correct Answer: B
B. A small change in protein binding can significantly increase free drug levels
, Rationale: Drugs that are highly protein-bound (≥90%) have only a small fraction of free
(unbound) drug available for pharmacologic activity. When protein binding is displaced by
another drug or altered by disease states (e.g., hypoalbuminemia, hepatic disease), the free
fraction can increase substantially, leading to toxicity. Only free drug is pharmacologically active
and available for distribution and elimination. Option A is incorrect because protein binding
delays onset since only free drug is active. Option C is incorrect because protein-bound drugs
are not readily filtered by the kidneys. Option D is incorrect because highly protein-bound drugs
often require dose adjustment in renal impairment if the active free fraction accumulates .
3. What does pharmacokinetics study?
A. The effects of drugs on the body
B. The movement of drugs through the body
C. Drug-receptor interactions
D. Drug toxicity mechanisms
Correct Answer: B
B. The movement of drugs through the body
Rationale: Pharmacokinetics encompasses the processes of absorption, distribution,
metabolism, and excretion (ADME). It describes what the body does to the drug. In contrast,
pharmacodynamics describes what the drug does to the body, including drug-receptor
interactions and effects. Option A describes pharmacodynamics. Option C describes
pharmacodynamics. Option D is a specific application within pharmacology but does not define
pharmacokinetics .
4. A drug has a half-life of 4 hours. Approximately how long will it take to reach steady state?
A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
Correct Answer: C
C. 20 hours
Rationale: Steady state is achieved after approximately 4–5 half-lives of drug administration.
With a half-life of 4 hours, steady state would be reached in approximately 20 hours (5 × 4 hours
,= 20 hours). At steady state, drug administration and elimination are balanced, resulting in
relatively constant drug levels. Option A (8 hours) represents only 2 half-lives. Option B (12
hours) represents 3 half-lives. Option D (40 hours) represents 10 half-lives, which is excessive .
5. A patient with decreased hepatic blood flow due to congestive heart failure is started on a
drug that undergoes extensive first-pass metabolism. How will the pharmacokinetics of this
drug most likely be altered?
A. Decreased oral bioavailability
B. Increased oral bioavailability
C. No change in oral bioavailability
D. Increased renal excretion
Correct Answer: B
B. Increased oral bioavailability
Rationale: In heart failure, decreased hepatic blood flow reduces the delivery of orally
absorbed drug to the liver, thereby reducing first-pass metabolism. This results in increased oral
bioavailability because less drug is metabolized before reaching systemic circulation. This may
require dose reduction to prevent toxicity. Option A is incorrect because decreased hepatic
blood flow would increase, not decrease, bioavailability. Option C is incorrect because hepatic
blood flow changes do affect first-pass metabolism. Option D is incorrect because renal
excretion is not the primary route affected by decreased hepatic blood flow .
6. Which of the following best describes the therapeutic index?
A. The ratio of a drug's toxic dose to its effective dose
B. The time required for a drug to produce its maximal effect
C. The amount of drug required to produce 50% of its maximal effect
D. The rate at which a drug is eliminated from the body
Correct Answer: A
A. The ratio of a drug's toxic dose to its effective dose
Rationale: The therapeutic index is the ratio of the toxic dose (TD50) to the effective dose
(ED50). A narrow therapeutic index indicates a small margin between therapeutic and toxic
doses, requiring close monitoring of serum drug levels. Examples include digoxin, warfarin,
, lithium, and phenytoin. Option B describes time to peak effect. Option C describes ED50
(median effective dose). Option D describes elimination rate constant .
7. A drug that binds to a receptor and produces a maximal response is termed:
A. Partial agonist
B. Antagonist
C. Full agonist
D. Inverse agonist
Correct Answer: C
C. Full agonist
Rationale: A full agonist binds to a receptor and produces a maximal biologic response. A
partial agonist produces a submaximal response even when occupying all receptors. An
antagonist binds to a receptor but produces no response and blocks the effects of agonists. An
inverse agonist produces an effect opposite to that of an agonist. Understanding these
distinctions is critical for predicting drug effects and interactions .
8. A patient is taking a medication that is a CYP3A4 inducer. This medication will:
A. Increase the metabolism of other drugs metabolized by CYP3A4
B. Decrease the metabolism of other drugs metabolized by CYP3A4
C. Have no effect on other drugs
D. Increase the absorption of other drugs
Correct Answer: A
A. Increase the metabolism of other drugs metabolized by CYP3A4
Rationale: CYP3A4 inducers increase the activity of the CYP3A4 enzyme, leading to
increased metabolism of drugs that are substrates for CYP3A4. This can reduce the serum
concentrations and therapeutic efficacy of those drugs. Examples of CYP3A4 inducers include
rifampin, phenytoin, carbamazepine, and St. John's wort. Option B describes enzyme inhibitors.
Option C is incorrect because inducers do affect other drugs. Option D is incorrect because
CYP450 enzymes affect metabolism, not absorption .
NURS 6521N Midterm Exam / NURS6521 Midterm Exam / NURS-
6521N Midterm Exam: Walden University | Correct Q and A
SECTION I: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–25)
1. A patient is prescribed a medication that undergoes extensive first-pass metabolism. The
nurse practitioner understands that this drug:
A. Will have increased bioavailability when administered orally
B. Will be metabolized in the liver before reaching systemic circulation
C. Must be administered intravenously to achieve any therapeutic effect
D. Will be excreted unchanged by the kidneys
Correct Answer: B
B. Will be metabolized in the liver before reaching systemic circulation
Rationale: First-pass metabolism occurs when an orally administered drug is absorbed from
the gastrointestinal tract and transported via the portal vein to the liver, where it undergoes
biotransformation before entering systemic circulation. This reduces the drug's oral
bioavailability. Drugs with extensive first-pass metabolism (e.g., nitroglycerin, morphine,
propranolol) often require higher oral doses or alternative routes of administration to achieve
therapeutic effects. Option A is incorrect because first-pass metabolism decreases, not
increases, oral bioavailability. Option C is incorrect because many drugs with first-pass
metabolism can still be given orally with appropriate dose adjustments. Option D is incorrect
because drugs undergoing first-pass metabolism are metabolized, not excreted unchanged .
2. A drug is 96% protein-bound. Which statement best describes the clinical implication of this
property?
A. The drug will have a rapid onset of action
B. A small change in protein binding can significantly increase free drug levels
C. The drug will be excreted more rapidly by the kidneys
D. The drug requires no dose adjustment in renal impairment
Correct Answer: B
B. A small change in protein binding can significantly increase free drug levels
, Rationale: Drugs that are highly protein-bound (≥90%) have only a small fraction of free
(unbound) drug available for pharmacologic activity. When protein binding is displaced by
another drug or altered by disease states (e.g., hypoalbuminemia, hepatic disease), the free
fraction can increase substantially, leading to toxicity. Only free drug is pharmacologically active
and available for distribution and elimination. Option A is incorrect because protein binding
delays onset since only free drug is active. Option C is incorrect because protein-bound drugs
are not readily filtered by the kidneys. Option D is incorrect because highly protein-bound drugs
often require dose adjustment in renal impairment if the active free fraction accumulates .
3. What does pharmacokinetics study?
A. The effects of drugs on the body
B. The movement of drugs through the body
C. Drug-receptor interactions
D. Drug toxicity mechanisms
Correct Answer: B
B. The movement of drugs through the body
Rationale: Pharmacokinetics encompasses the processes of absorption, distribution,
metabolism, and excretion (ADME). It describes what the body does to the drug. In contrast,
pharmacodynamics describes what the drug does to the body, including drug-receptor
interactions and effects. Option A describes pharmacodynamics. Option C describes
pharmacodynamics. Option D is a specific application within pharmacology but does not define
pharmacokinetics .
4. A drug has a half-life of 4 hours. Approximately how long will it take to reach steady state?
A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
Correct Answer: C
C. 20 hours
Rationale: Steady state is achieved after approximately 4–5 half-lives of drug administration.
With a half-life of 4 hours, steady state would be reached in approximately 20 hours (5 × 4 hours
,= 20 hours). At steady state, drug administration and elimination are balanced, resulting in
relatively constant drug levels. Option A (8 hours) represents only 2 half-lives. Option B (12
hours) represents 3 half-lives. Option D (40 hours) represents 10 half-lives, which is excessive .
5. A patient with decreased hepatic blood flow due to congestive heart failure is started on a
drug that undergoes extensive first-pass metabolism. How will the pharmacokinetics of this
drug most likely be altered?
A. Decreased oral bioavailability
B. Increased oral bioavailability
C. No change in oral bioavailability
D. Increased renal excretion
Correct Answer: B
B. Increased oral bioavailability
Rationale: In heart failure, decreased hepatic blood flow reduces the delivery of orally
absorbed drug to the liver, thereby reducing first-pass metabolism. This results in increased oral
bioavailability because less drug is metabolized before reaching systemic circulation. This may
require dose reduction to prevent toxicity. Option A is incorrect because decreased hepatic
blood flow would increase, not decrease, bioavailability. Option C is incorrect because hepatic
blood flow changes do affect first-pass metabolism. Option D is incorrect because renal
excretion is not the primary route affected by decreased hepatic blood flow .
6. Which of the following best describes the therapeutic index?
A. The ratio of a drug's toxic dose to its effective dose
B. The time required for a drug to produce its maximal effect
C. The amount of drug required to produce 50% of its maximal effect
D. The rate at which a drug is eliminated from the body
Correct Answer: A
A. The ratio of a drug's toxic dose to its effective dose
Rationale: The therapeutic index is the ratio of the toxic dose (TD50) to the effective dose
(ED50). A narrow therapeutic index indicates a small margin between therapeutic and toxic
doses, requiring close monitoring of serum drug levels. Examples include digoxin, warfarin,
, lithium, and phenytoin. Option B describes time to peak effect. Option C describes ED50
(median effective dose). Option D describes elimination rate constant .
7. A drug that binds to a receptor and produces a maximal response is termed:
A. Partial agonist
B. Antagonist
C. Full agonist
D. Inverse agonist
Correct Answer: C
C. Full agonist
Rationale: A full agonist binds to a receptor and produces a maximal biologic response. A
partial agonist produces a submaximal response even when occupying all receptors. An
antagonist binds to a receptor but produces no response and blocks the effects of agonists. An
inverse agonist produces an effect opposite to that of an agonist. Understanding these
distinctions is critical for predicting drug effects and interactions .
8. A patient is taking a medication that is a CYP3A4 inducer. This medication will:
A. Increase the metabolism of other drugs metabolized by CYP3A4
B. Decrease the metabolism of other drugs metabolized by CYP3A4
C. Have no effect on other drugs
D. Increase the absorption of other drugs
Correct Answer: A
A. Increase the metabolism of other drugs metabolized by CYP3A4
Rationale: CYP3A4 inducers increase the activity of the CYP3A4 enzyme, leading to
increased metabolism of drugs that are substrates for CYP3A4. This can reduce the serum
concentrations and therapeutic efficacy of those drugs. Examples of CYP3A4 inducers include
rifampin, phenytoin, carbamazepine, and St. John's wort. Option B describes enzyme inhibitors.
Option C is incorrect because inducers do affect other drugs. Option D is incorrect because
CYP450 enzymes affect metabolism, not absorption .
